

What is Peptide Receptor Radionuclide Therapy (PRRT)?

PRRT delivers radiation directly to the tumor to kill cancer cells.

Some NET cells have proteins on their cell surface called receptors that can bind to hormones such as somatostatin, PRRT with lutetium 177 dotatate (Lu-177) targets these receptors.

What are the benefits of PRRT?

PRRT was approved in the US in 2018 to treat adults with pancreatic and gastrointestinal NETs. Patients should test positive for somatostatin receptors to benefit from PRRT. A Gallium 68-Dotatate PET/CT can help to determine the presence of these receptors.

Studies have shown PRRT can:

- Increase progression-free survival and likely survival
- Improve the quality of life
- Relieve symptoms
- Decrease tumor size

What are the side effects of PRRT? PRRT is generally well tolerated.

Common side effects of radiopeptide therapy are:

- Nausea
- Vomiting
- Abdominal pain
- Fatigue

More serious side effects, such as bone, liver, and kidney toxicity, are less common.

